GLUE

News Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments

14d ago

SEC filing GLUE Reports $671M Cash, $19B Revenue, +94% CRP Drop, Phase 2 Initiations in H2 2026

26d ago

Insider trade Sale by Markus Warmuth (President & CEO)

27d ago

Insider trade Sale by Markus Warmuth (President & CEO)

47d ago

Insider trade Sale by Philip Nickson (Chief Business & Legal Officer)

52d ago

SEC filing GLUE Monte Rosa Reports $345M Upsized Financing, $19.3M Net Income, +94% CRP Reduction in CVD Study

77d ago

News Monte Rosa rises on J&J collaboration for cancer therapy trial

78d ago

Insider trade Sale by Edmund Dunn (Principal Accounting Officer)

88d ago

Insider trade Sale by Markus Warmuth (President & CEO)

89d ago

Insider trade Sale by Edmund Dunn (Principal Accounting Officer)

91d ago

SEC filing GLUE Announces Edmund Dunn's Retirement as SVP, Corporate Controller; Matthew Bowen Appointed Successor Effective April 3, 2026

111d ago

News 3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher

116d ago

News Unusually Sticky Options Trade in $GLUE Jumps +772%

137d ago

News Monte Rosa Therapeutics announces pricing of $300M stock offering

144d ago

News Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

144d ago

News Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

145d ago

News Monte Rosa Therapeutics launches $200M public equity offering

145d ago

News Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases

153d ago

News Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

153d ago

Scanner Unusual volume (z=4.5)

160d ago

Scanner Unusual volume (z=4.8)

162d ago

Scanner Unusual volume (z=4.8)

163d ago

Scanner Unusual volume (z=4.8)

164d ago

SEC filing GLUE Reveals 100% PSA Response for MRT-2359 in Prostate Cancer, Plans Phase 2 Study

168d ago